Selecta Biosciences Secures $20,000,000 New Funding Round

  • Feed Type
  • Date
    10/15/2014
  • Company Name
    Selecta Biosciences
  • Mailing Address
    480 Arsenal St. Building One Watertown, MA 02472 USA
  • Company Description
    Selecta Biosciences, Inc. is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications.
  • Website
    http://www.selectabio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $20,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    With strong financial support from both our current and new investors, we are now well positioned to rapidly advance our immune tolerance pipeline, including the lead program SEL-212, the first non-immunogenic treatment for refractory and tophaceous gout.
  • M&A Terms
  • Venture Investor

Trending on Xconomy